The iconic rise of Viagra has long been a benchmark of pharmaceutical success, but its position within the broader market now presents questions about future yields . Copycat versions are diminishing patent protection , causing worries that betting on companies heavily reliant to Viagra's previous influence could be a dangerous decision , especiall